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1.1 PURINERGIC TRANSMISSION 
 
Purines and pyrimidines have widespread and specific 
extracellular signalling actions in the regulation of a variety of 
biologic functions in many tissues. For many years, the focus of 
interest in purines and pyrimidines has been the involvement of 
ATP in cell metabolism and its role as an energy source. The 
concept that ATP is an extracellular signalling molecule took a 
long time to be accepted (Abbracchio and Burnstock, 1998). With 
the development of new research tools, such as molecular cloning, 
purinergic signalling has become an established principle not only 
in the rapid signalling involved in neurotransmission, but also in a 
wide range of other biological processes, including release of 
cytokines and hormones (Firestein et al., 1996; Rasi et al., 1996), 
regulation of cell proliferation, differentiation and apoptosis in 
tissues as diverse as the skin, skeletal muscle, bone, nervous and 
immune system (Abbracchio et al., 1996). Thus, alterations in 
purinergic signalling may contribute to the development of several 
diseases, in particular disorders of the immune system, 
inflammation, cardiac ischemia, neurodegeneration, osteoporosis, 
cancer and many others. On this basis, the understanding of the 
precise role of purinergic signalling in various organs and systems 
may help the identification of novel targets for the development of 
more effective therapeutic approaches to currently incurable 
human diseases. 
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1.1.1 Purines and pyrimidines 
It has been demonstrated that, following mechanical stress, non 
secretory tissues can also release nucleotides (Lazarowski et al., 
2000) that may signal to the same secretory cell (autocrine 
stimulation) as well as to adjacent cells (paracrine stimulation). 
Following injury, extracellular adenine (purine) and uracil 
(pyrimidines) nucleotides can be released as a consequence of cell 
lysis. In these circumstances, ATP can reach millimolar 
concentrations in the extracellular milieu, although in 
physiological conditions relatively low concentrations of the 
nucleotide can induce rapid and specific responses. Like adenine 
nucleotides, uracil nucleotides regulate a broad range of functions: 
nervous cell excitation, muscle cell proliferation, endothelial 
adhesion, leukocyte chemotaxis, spermatogenesis, hormones and 
histamine release, acid balance in epithelial intestinal cells, 
mucociliary clearance in airway epithelium, and superoxide 
production. Furthermore, basal release of UTP from human 
platelets has been described (Lazarowski and Harden, 1999), 
suggesting a role for this nucleotide in endothelial and muscular 
cell stimulation during thrombosis. More recently, during 
myocardial infarction, human venous plasma levels of UTP have 
been also demonstrated to be released (Wihlborg et al., 2006) and 
in vivo experiments in the rat have shown  that UTP reduces 
infarct size and improves myocardial function (Shainberg et al., 
2009). Once released in the extracellular environment, nucleotides 
are rapidly degraded by ubiquitous ecto-nucleotidases 
(Zimmermann, 2000), a family of phosphatases expressed on the 
cell surface that are able to metabolize different nucleotides. ATP 
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hydrolysis produces ADP, AMP and adenosine, whether UTP is 
degraded to UDP, UMP and uridine. All these metabolites can 
function as extracellular signalling molecules, thus tissue response 
to nucleotide release is the result of the effects of the nucleotide 
and of its degradation products on target cells. Distinct classes of 
ecto-nucleotidases with different properties and different substrate 
specificities have been identified so far (Zimmermann, 1999). 
Some are membrane proteins, but soluble forms released in the 
extracellular milieu following a proteolytic process have also been 
described. Ecto-nucleotidases can also be released with ATP from 
sympathetic nerve terminals and they represent one of the 
mechanisms used to turn off neurotransmitter signalling (Todorov 
et al., 1997). There is a significant increase in ectonucleotidase 
activity (NTPdaseI) in the hearts of patients with ischaemic heart 
disease (Kittel et al., 2005) that could represent a compensatory 
mechanism against increased nucleotide levels during chronic 
ischaemia. 
 
1.1.2 Purinergic receptors 
Based on the actions of purine nucleotides in a wide variety of 
tissue, in 1978, Burnstock proposed some criteria for the 
classification of purinergic receptors in two families: the P1 
receptors, selectively activated by adenosine and the P2 receptors, 
responding to ATP and ADP. The distinction between P1 and P2 
receptors has been officially approved and has been adopted by 
the International Union of Pharmacology (IUPHAR) 
Subcommittee for the Nomenclature and Classification of 
Purinoceptor and is now universally used (Abbracchio and 
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Burnstock, 1994; Fredholm et al., 1997). Four members of the P1 
family of G protein-coupled receptors have been identified (A1, 
A2A, A2B and A3; (Fredholm et al., 1994) and 15 members of the 
P2 family have been cloned so far (Abbracchio et al., 2006; Khakh 
and Henderson, 2000). A further classification was suggested for 
P2 receptors on the basis of their pharmacological profiles 
(Burnstock, 2006), and on their vascular effects (some induce 
vasoconstriction whereas others mediate an opposite effect). 
Further studies have led to a better structural characterization of 
the P2 receptors and to the distinction between ionotropic 
purinergic receptors mediating rapid effects and metabotropic P2 
receptors with a later onset of response (Dubyak, 1991). In 1994, 
together with the cloning of the first members of the family, a new 
classification of P2 receptors was proposed (Abbracchio and 
Burnstock, 1994). Two main groups were identified, the P2X 
family of ligand-activated channels and the G protein-coupled 
P2Y receptors. This new classification allows to compare 
purinergic transmission to acetylcholine, glutamate, serotonin and 
GABA systems, which are known to involve both metabotropic 
and ionotropic receptors (Abbracchio and Burnstock, 1998). Up to 
date, at least 7 P2X subtypes (P2X1-7) and 8 P2Y members 
(P2Y1,2,4,6,11,12,13,14) have been cloned from different animal 
species (Abbracchio et al., 2006). The missing numbers in the P2Y 
series correspond to receptors cloned from vertebrates different 
from mammals and for which no mammalian orthologs have been 
identified so far, or to receptors that have not yet been functionally 
characterized. Recently, a new putative member of the P2Y 
receptor family, previously known as the “orphan” receptor 
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GPR17, has been identified and has been showed to be specifically 
activated by both uracil nucleotides (UDP, UDP-glucose and 
UDP-galactose) and cysteinyl-leukotrienes (cysLTs) (Ciana et al., 
2006). 
 
1.1.2.1 P2X receptors 
P2X receptors are membrane ion channels that contain intrinsic 
pores that switch conformation from closed to open on binding 
ATP, allowing ions to flow. The flow of ions is a key step in 
signalling, because it changes the trasmembrane potential as well 
as local ion concentrations (Khakh and North, 2006). ATP can 
elicit rapid responses (<10ms) via these ion channels, resulting in 
selective permeability to Na+, K+, and Ca2+ cations (North, 
2002). In vertebrates, seven genes encode P2X receptor subunits, 
which are 40–50% identical in amino acid sequence. The seven 
P2X subunits range from 379 (P2X6) to 595 (P2X7) amino acids in 
length. Each subunit has two hydrophobic, putative membrane-
spanning segments (TM1 and TM2) of sufficient length to cross 
the plasma membrane, separated by an ectodomain that contains 
10 conserved cysteine residues which form disulfide bonds to give 
the correct conformation to the receptor (Clyne et al., 2002; 
Ennion and Evans, 2002; Vial et al., 2004). The ectodomain 
(about 300 residues) is thought to form an extracellular loop 
containing the ATP binding site and sites for antagonists and 
modulators (Khakh et al., 2001). The NH2 and COOH termini are 
intracellular (Newbolt et al., 1998; Stoop et al., 1999; Torres et al., 
1998) and comprise the cytosolic domain. The C-terminal regions 
diverge in sequence considerably. This topology is the simplest 
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among ionotropic receptors (Figure 1.1). The amino acid identity 
between P2X receptor subunits is distributed throughout the 
extracellular domain. All the P2X receptor subunits have 
consensus sequences for N-linked glycosylation (Asn-X-Ser/Thr), 
and some glycosylation is essential for trafficking to the cell 
surface. The extracellular domain carries few conserved glycine 
(G) and proline (P) residues which are involved in conformational 
changes subsequent to the ligand-receptor binding. Extracellular 
protons, bivalent cations and some metals are P2X receptors 
allosteric modulators. In addition, P2X receptors can be modulated 
via the phosphorylation of serine (S) and threonine (T) residues. 
Functional expression studies have highlighted the existence of 
heteromeric, P2X1/5, P2X2/3, P2X2/6, P2X4/6, P2X4/7 and P2X5 
receptors which assemble with any others, except P2X7 (Guo et 
al., 2007; North, 2002). With the use of pharmacology and gene 
knock-out/down approaches, it has also become clear that P2X 
receptors are involved in a wide and growing range of 
pathophysiological processes (Khakh and North, 2006). 
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Figure 1.1: Schematic representation of a P2X receptor. 
An individual subunit showing the two transmembrane structure and amino 
acid residues that are implicated in ligand binding and that maintain the 
conformation of the subunit (modified from Khakh et al., 2006) 
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1.1.2.2 P2Y receptors 
P2Y receptors belong to the superfamily g protein-coupled 
receptors (GPCR). GPCRs are a family of membrane receptors 
responding to a wide variety of ligands such as nucleotides, 
biogenic amines, peptides and other small molecules (Marchese et 
al., 1999). The binding of the GPCR to its specific ligand results in 
the activation of the associated heterotrimeric (α, β and γ subunits) 
G protein that can mediate a number of intracellular responses. In 
particular, ligand binding to its receptor results in a decreased 
affinity of the α subunit of the G protein for GDP, that is thus 
released and substituted for by GTP. This binding causes a 
conformational modification in the G protein and the dissociation 
of the α subunit from the βγ complex. Both α and βγ subunits can 
activate signal transduction pathways (Rebois et al., 1997). The 
receptor proteins of the P2Y receptor subtypes contain the typical 
features of GPCRs including 7 predicted hydrophobic 
transmembrane regions (TMs) connected by 3 extracellular loops 
(ELs) and 3 intracellular loops. The proteins of the human 
receptors consist of 328 (P2Y6) to 377 (P2Y4) amino acids 
corresponding to a predicted molecular mass of 41-53 kDa of the 
glycosylated proteins. The biochemical analysis of the P2Y-
receptor proteins has shown that at the level of the cell membrane 
are modified by N-linked glycosilation (Erb et al., 1995). All 
know P2Y-receptor subtypes possess at their extracellular domains 
4 cysteine residues, which are likely to form 2 disulfide bridges. 
The P2Y receptor-family shows a relatively high diversity in the 
amino acid composition to P2X receptors and in contrast, P2Y 
receptor genes do not contain introns in the coding sequence, 
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except for the P2Y11 receptor. Site-directed mutagenesis of the 
P2Y1 and P2Y2 receptors has shown that some positively charged 
residues in transmembrane domains 3, 6 and 7, which are 
localized close to intracellular loops, are crucial for receptor 
activation by nucleotides (Erb et al., 1995; Jiang et al., 1997). 
They probably interact with the negative charges of the phosphate 
groups of nucleotides. Actually, the eight P2Y receptors identified 
so far have a H-x-x-R/K motif in TM6 that might be important for 
agonist activity (Figure 1.2). 
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Figure 1.2: Schematic representation of a P2Y receptor showing the seven 
transmembrane structure and amino acidic residues that are implicated in 
ligand binding. 
Model shows features of the hP2Y1 receptor important for nucleotide binding 
both within the TMs (3, 6, and 7) and ELs (2 and 3), four Cys residues (-S), 
which are conserved among P2Y subtypes, form disulfide bridges. The 
location of the putative glycosylation site is conserved within the P2Y family. 
Modulatory residues for the activation of the P2Y1 receptor are also shown. 
TM = transmembrane; EL= extracellular loop (modified from Jacobson et 
al., 2002). 
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From a phylogenetical point of view, the eight human P2Y 
receptors can be subdivided into two distinct subgroups 
characterized by a relatively high level of sequence divergence. 
The first subgroup encompasses P2Y1, P2Y2, P2Y4, P2Y6 and 
P2Y11, whereas the second subgroup encompasses P2Y12, P2Y13 
and P2Y14 (Abbracchio et al., 2006). Receptors in the first 
subgroup also share a YQ/ K-x-x-R motif in TM7 (proposed to 
participate in ligand binding), whereas in receptors of the second 
subgroup another motif (K-E-x-x-L) which might affect ligand 
binding characteristics is found (Abbracchio et al., 2006). These 
two P2Y receptor subgroups also differ in their primary coupling 
to transductional G proteins. In particular, receptors in the first 
subgroup (i.e., P2Y1,2,4,6,11) all principally use Gq/G11 to activate 
PLCβ/IP3 pathway and release intracellular calcium, whereas 
receptors in the second subgroup (i.e., P2Y12,13,14) almost 
exclusively use the Gi/o class of G proteins to lower cAMP levels. 
Secondary couplings have been also reported, especially for 
receptors of the first subgroup in heterologous expression systems 
(Kottgen et al., 2003; Simon et al., 2002; White et al., 2003). 
Among receptors of the second group, P2Y13 has been also 
reported to couple to Gα16 and stimulate phospholipase C in 
recombinant systems overexpressing this G protein (Communi et 
al., 2001; Marteau et al., 2003);(Fumagalli et al., 2004). Such 
“promiscuity” of G protein coupling may depend on the indirect 
activation of additional G protein subtypes within protein 
complexes containing the P2Y receptor. 
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1.1.2.3 Pharmacological features of P2Y receptors 
There is increasing interest in the expression of P2Y receptors in 
pathological conditions and in the therapeutic potential of P2Y 
receptor related compounds. Both P2Y1 and P2Y12 receptors 
costitute targets for antithrombotic therapy; progress in exploring 
structure-activity relationships has been achieved for these 
receptors and to a lesser extent for the P2Y2 receptor. However, 
most of the P2Y receptor subtypes are still lacking potent and 
selective synthetic agonists and antagonists (Abbracchio et al., 
2006). 
 
1.1.2.3.1 ADP- preferring receptors: P2Y1, P2Y12, P2Y13  
ADP is the natural agonist at the P2Y1, P2Y12, and P2Y13 
receptors, and it interacts at these subtypes with generally greater 
affinity than does ATP (Marteau et al., 2003; Palmer et al., 1998). 
At P2Y1 receptors, derivatives of adenosine 5′-diphosphate tend to 
be full agonists, while ATP appears to be a partial agonist. At 
P2Y12 receptors, adenosine 5′-diphosphate derivatives act as 
agonists, and 5′-triphosphate derivatives act as antagonists 
(Gachet, 2005). At P2Y13 receptors, both ADP and ATP appear to 
be full agonists; at the P2Y1 receptor, 2-MeSADP has been used 
widely for activation, but this compound also activates the P2Y12 
and P2Y13 receptors. Notably, the 20-deoxy N6-methyl derivative 
MRS2179 is a protypical selective P2Y1 antagonist. The favored 
ribose-ring conformation for each of the subtypes of the P2Y1-like 
family has been established using conformationally restricted 
ribose equivalents. The later generation of synthetic bisphosphate 
antagonists incorporates a rigid substitute for the normally flexible 
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ribose ring. MRS2279 and MRS2500 are generally useful as 
selective, high-affinity antagonists of the P2Y1 receptor in various 
species (Kim et al., 2003). The (N)-methanocarba ring in these 
nucleotide analogs both enhances receptor affinity and improves 
stability toward nucleotidases. Antagonists of the P2Y1 receptor of 
moderate affinity might also be derived from acyclic nucleotides 
(bisphosphates and bisphosphonates), such as MRS2496 (Costanzi 
et al., 2007). The screening of structurally diverse chemical 
libraries by the pharmaceutical industry has led to non-nucleotide 
antagonists of the P2Y1 receptor (Pfefferkorn et al., 2008). A 
tetrahydro-4-quinolinamine derivative inhibited the P2Y1 receptor 
effects and platelet aggregation (Morales-Ramos et al., 2008). 
Extensive structure-activity studies of ATP derivatives as 
antagonists of the platelet P2Y12 receptor resulted in high-affinity 
selective antagonists of interest as antithrombotic agents. The 
thienopyridines, such as clopidogrel, were serendipitously 
identified as inhibitors of platelet aggregation by ADP 20 years 
before the cloning and identification of their target, the P2Y12 
receptor. They act as liver-activated prodrugs, the active 
metabolites of which are irreversible inhibitors of the P2Y12 
receptor. A drug development program by AstraZeneca to design 
P2Y12 receptor antagonists has introduced numerous directly 
acting P2Y12 receptor antagonists. The observation that ATP acts 
as an antagonist at this ADP-activated subtype has enabled the 
introduction of various 50-triphosphate analogs as selective 
receptors probes, and one of them, AR-C69931MX 42 
(Cangrelor), has been tested clinically as an antithrombotic agent. 
One of the products of this effort is ticagrelor 43 (AZD6140), an 
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uncharged nucleoside derivative with a high affinity at the P2Y12 
receptor, which is currently in clinical trials (Springthorpe et al., 
2007; Tantry et al., 2007)(Wallentin, 2009). The search for 
selective non-nucleotide antagonists of the P2Y12 receptor, for 
potential use as antithrombotic agents, is continuing. The agonist 
potency at the P2Y13 receptor is ADP > 2-MeSADP > ATP. A 
selective P2Y13 receptor antagonist MRS2211 is a derivative of 
PPADS, a nonselective P2Y and P2X receptor antagonist derived 
from pyridoxal phosphate (Kim et al., 2005). MRS2211 has the 
disadvantage of containing a phosphate ester group and an aryl 
diazo linkage, both of which are subject to instability in tissue 
systems. The nonselective P2X/P2Y antagonist Reactive blue 2 
(RB2) and its derivatives are known to block action at P2Y1 
receptors, however high potency and selectivity have not been 
achieved (Brown and Brown, 2002; Jacobson et al., 2002). The 
polysulfonate suramin and its derivatives, in addition to displaying 
trypanocidal drug properties, are relatively nonselective P2 
antagonist with, in general, reversibility upon washout. Within the 
P2Y family, suramin has been characterized as an antagonist of 
P2Y2 receptors (Wildman et al., 2003). Derivatives of PPADS 
have also been shown to antagonize P2Y1 receptor effects in a 
competitive fashion, although at micromolar concentrations 
(Lambrecht et al., 2002). Most of the ligands of P2Y receptors 
identified so far are polyanionic molecules that do not readily 
cross the cell membrane. This raises a major problem of 
bioavailability, this lack of systemic action can be an asset in case 
of topical applications, such as spray or eye drops. The hydrolysis 
of nucleotide compounds by ectonucleotidases constitutes another 
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limiting factor partially overcome by the development of more 
stable dinucleotide compounds. Orally active uncharged 
antagonists (e.g. thienopyridines and ticagrelor) are available only 
for the P2Y12 receptor. 
 
1.1.2.3.2 ATP preferring receptors: P2Y11 
ATP is the preferred native ligand at P2Y11 receptors (Communi et 
al., 1999), and ATP-γ-S is a more potent agonist than ATP. The 
P2Y12 antagonist AR-C69931MX 42 (cangrelor) acts as a potent 
agonist at the P2Y11 receptor (Boeynaems et al., 2005). Selective 
antagonists of the P2Y11 receptors are still unknown. P2Y11 is not 
expressed in rodents. 
 
1.1.2.3.3 Selective receptor for UDP: P2Y6 
Uridine 5′-diphosphate derivatives activate the P2Y6 receptor 
more potently than the corresponding 5′-triphosphates (Malmsjo et 
al., 2000; Muller, 2002); thus, UDP is a selective agonist at this 
subtype. The β-thiodiphosphate was shown to be more potent than 
UDP in activation of the P2Y6 receptor and more stable to 
degradation. Various diisothiocyante derivatives were found to be 
potent antagonist of human P2Y6 as well as other P2Y receptors 
(Mamedova et al., 2004). A 1,4-di-(phenylthioureido) butane 
derivative (MRS2578) selectively inhibited UDP-induced PLC 
activity through both human and rat P2Y6 receptors expressed in 
1321N1 human astrocytes and was inactive at human P2Y1, P2Y2, 
P2Y4 and P2Y11 receptors. 
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1.1.2.3.4 Receptors with mixed selectivity: P2Y2 and P2Y4 
The P2Y2 receptor is activated nearly equipotently by UTP and 
ATP but is not activated by the corresponding 5′-diphosphates, 
i.e., UDP and ADP. The P2Y4 receptor is primarily activated by 
uracil nucleotides, depending on the species. In the rat, ATP is 
also a P2Y4 agonist, but in humans it acts as a P2Y4 antagonist. 
Uridine β-thiodiphosphate (UDP- β-S) and the γ-thiophosphate 
(UTP-γ-S) are selective agonists for P2Y6 and P2Y2/P2Y4 
receptors, respectively (Malmsjo et al., 2000). Numerous 
substitutions of the uracil ring of UTP have been reported to 
reduce potency at the P2Y2 receptor (Muller, 2002). The adenine 
dinucleotide Ap4A is a potent agonist at the rat P2Y4 receptor and 
is less potent than ATP at the P2Y2 receptor. Other uracil 
dinucleotides, such as INS365 (Up4U), also potently activate the 
P2Y2 receptor (Shaver et al., 2005). The dependence of potency at 
various P2Y receptors on the number of bridging phosphate units 
in the dinucleotide series indicates an optimum at the 
tetraphosphate. Newer-generation P2Y2 receptor agonists, such as 
INS37217 (Up4dC), have been reported (Pendergast et al., 2001; 
Yerxa et al., 2002). P2Y2 receptor agonists are of clinical interest 
for the treatment of pulmonary and ophthalmic diseases and 
possibly cancer. Suramin is a weak antagonist at the P2Y2 receptor 
with an IC50 of 48 μM (Muller, 2002). At concentration of 100 
μM, reactive blue-2 effectively blocks rat P2Y4 receptors, but only 
partially blocks human P2Y4 receptors. Flavonoids have been 
identified as a new lead for the design of P2Y2 receptor 
antagonists. AR-C118925, is reported to selectively antagonize 
P2Y2 receptor (Jacobson and Boeynaems). 
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1.1.2.3.5 Receptor for sugar nucleotides: P2Y14 
The most recently cloned receptor, P2Y14, responds to UDP-
glucose and has a sequence more similar to the P2Y12 and P2Y13 
receptors than to the other P2Y subtypes (Abbracchio et al., 2003). 
The P2Y14 receptor is also activated by UDP-galactose, UDP-
glucuronic acid and UDP-N acetylglucosamine (Chambers et al., 
2000). Of these endogenous ligands, to date only UDP-glucose has 
been shown to be released extracellularly by a variety of cell lines 
(Lazarowski et al., 2003). At present, no selective antagonists are 
available, although it has to be underlined that the currently 
available P2 receptor antagonists have not been tested on this 
receptor. 
 
1.1.2.3.6 New P2Y receptor for uracil nucleotides: GPR17 
The recently deorphanized P2Y- like receptor GPR17 has been 
reported to respond to both uracil nucleotides and cysteinyl-
leukotrienes, such as UDP-glucose and LTD4 (Ciana et al., 2006). 
GPR17 is expressed in organs typically undergoing ischemic 
damage (i.e., brain, heart and kidney), thus representing a new 
pharmacological target for acute and chronic neurodegeneration.  
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1.2 HEART ISCHEMIC DISEASE 
 
Cardiovascular diseases (CVD) have emerged as dominant chronic 
disease in western countries. In the 21
st
 century, CVD are also 
predicted to become the main cause of disability and death 
worldwide. In Europe, every year CVD kills 2 million of people, 
250.000 only in Italy. Ischemic heart disease refers to a lack of 
oxygen due to inadequate perfusion of the myocardium, which 
causes an imbalance between oxygen supply and demand. 
Myocardial ischemia occurs at virtually any age, but the frequency 
rises progressively with increasing age (especially men over 40 
and women over 50) and with presence of important risk and 
lifestyle factors that predispose to atherosclerosis, such as 
hypertension, smoking, diabetes mellitus, obesity, genetic 
hypercholesterolemia, and other causes of hyperlipoproteinemia. 
The most common cause of myocardial ischemia is obstructive 
atherosclerosis disease of epicardial coronary arteries (Figure 1.3).  
 
1.2.1 Atherosclerosis 
Atherosclerosis is the main cause of ischaemic stroke and 
cardiovascular disease and is now considered to be an 
inflammatory disease (Hansson, 2005). The formation of a plaque 
starts with the accumulation of cholesterol followed by invasion of 
macrophages taking up cholesterol and becoming foam cells. The 
plaque can be stabilised by smooth muscle cell formation of a 
fibrous cap that covers the lipid-rich region. However, stimulation 
of inflammation by oxidised lowdensity lipoprotein activates 
macrophages and dendritic cells into antigen-presenting cells, 
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activating T lymphocytes, resulting in release of cytokines and 
metalloproteinases degrading the fibrous cap. The end result is a 
vulnerable plaque and, when it ruptures, its highly thrombogenic 
contents activates platelets and causes the formation of a local 
thrombus occluding the artery or embolising, resulting in 
ischaemic stroke or myocardial infarction. Upon occurrence of 
inadequate myocardial perfusion caused by coronary 
atheroslerosis, myocardial tissue oxygen tension falls and causes 
transient disturbances of mechanical, biochemical and electrical 
function of the myocardium. The abrupt development of severe 
ischemia is associated with almost instantaneous failure of normal 
muscle contraction and relaxation.  
 
1.2.2 Ischemic diseases classification 
When ischemia is transient, it may be associated with angina 
pectoris, when it is prolonged can lead to acute myocardial 
infarction (MI). Patients with ischemic heart disease fall into two 
large groups: 
1- patients with stable angina secondary to chronic coronary artery 
disease; 
2- patients with acute coronary syndromes (ACS). The latter is 
composed of: 
a. patients with acute myocardial infarction (MI) with ST-segment 
elevation on their presenting electrocardiogram (STEMI)  
b. patients with unstable angina (UA) and non ST-segment 
elevation MI (UA/NSTEMI).  
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a. UA/NSTEMI is associated to a reduction in oxygen supply 
and/or an increase in myocardial oxygen demand superimposed on 
a coronary obstruction. This condition is normally an aggravation 
of a stable coronary artery disease and requires medical or 
mechanical interventions.  
 
b. STEMI generally occurs when coronary blood flow decreases 
abruptly after a thrombotic occlusion of a coronary artery 
previously affected by atherosclerosis. STEMI occurs when a 
coronary artery thrombus develops rapidly at a site of vascular 
injury. In most cases, infarction occurs when an atherosclerotic 
plaque fissures, ruptures, or ulcerates and when conditions favor 
thrombogenesis, so that a mural thrombus forms at the site of 
rupture and leads to coronary artery occlusion. The extension of 
myocardial damage and scar formation caused by coronary 
occlusion depends on: 
1- the territory supplied by the affected vessel 
2- whether the vessel becomes totally or partially occluded 
3- the duration of coronary occlusion 
4- blood quantity supplied by collateral vessels to the infarcted 
tissue 
5- the myocardium oxygen demand whose blood supply has been 
suddenly limited 
6- native factors that can produce early spontaneous lysis of the 
occlusive thrombus 
7- the adequacy of myocardial perfusion in the infarct zone when 
flow is restored in the occluded epicardial coronary artery. 
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Figure.1.3: Coronary angiogram. It is possible to observe a 
severe proximal stenosis of the left descending coronary artery 
due to an atherosclerotic plaque. 
 
1.2.3 Injury in the pathogenesis of ischemic disease 
Because oxygen delivery to the heart is closely coupled to 
coronary blood flow, a sudden arrest of regional perfusion 
following a thrombotic coronary occlusion quickly leads to the 
suspension of aerobic metabolism, depletion of creatine 
phosphate, and the onset of anaerobic glycolysis. This is followed 
by the accumulation of tissue lactate, a progressive reduction in 
tissue ATP levels, and a accumulation of catabolites. As ischemia 
continues, tissue acidosis develops and there is an efflux of 
potassium into the extracellular space. Subsequently, ATP levels 
fall below those required to maintain critical membrane function, 
resulting in the onset of myocyte death. The temporal evolution 
and extent of irreversible tissue injury is variable and dependent 
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on trasmural location, residual coronary flow, and the 
hemodynamic determinants of oxygen cosumption. Irreversible 
injury begins after 20 minutes of coronary occlusion in the 
absence of significant collaterals (Kloner and Jennings, 2001). 
Factors that increase myocardial oxygen consumption (e.g., 
tachycardia) or reduce oxygen delivery (e.g., anemia, arterial 
hypotension) accelerate the progression of irreversible injury. 
Reperfusion immediately causes myocytes necrosis and 
sarcolemmal disruption, with the leakage of cell contents into the 
extracellular space. The injury is further amplified by the reentry 
of leukocytes into the area of injury. At later time points, 
myocytes initially salvaged can undergo apoptosis, which can 
contribute to further delayed myocardial injury. 
 
1.2.4 Myocyte cell death 
Cell death arises from distinct mechanisms in myocardial 
infarction. It has been reported to have features of apoptosis, 
necrosis and autophagy.  
 
1.2.4.1 Apoptosis 
Apoptosis, or programmed cell death, is an evolutionary 
conserved process that allows multicellular organisms to 
selectively remove cells through a highly orchestrated program of 
cell suicide. The ensemble of proteins that are responsible for 
activating apoptosis is preprogrammed into the genetic code of the 
cells that are destined to die. However, under pathological 
circumstances such as acute ischemia, the apoptotic program can 
be triggered inappropriately, resulting in inadvertent cell death. 
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Apoptosis requires energy and activation of specific biochemical 
steps that are involved in triggering and executing cell death 
through activation of “intrinsic (mitochondrial) and “extrinsic” 
(death receptor mediated) pathway that both lead to the activation 
of executioner caspases (Figure 1.4). The extrinsic pathway is 
specialized to trasduce signals from soluble and cell-bound death 
ligands, which bind and activate their cell surface death receptors 
(Peter and Krammer, 2003). The more ancient intrinsic pathway is 
responsible for trasducing most apoptotic stimuli converging at the 
mitochondria to trigger the release of apoptogenic proteins and at 
endoplasmic reticulum (ER) to stimulate the release of luminal 
calcium (Scorrano et al., 2002). During apoptosis the cell shrinks 
and eventually breaks up into small, membrane-surronded 
fragments. The latter often contain bits of condensed chromatin, 
referred to as apoptotic bodies. Maintenance of plasma membrane 
integrity until late in the apoptotic process allows the dying cell to 
be engulfed by macrophages, which prevents the release of the 
reactive intracellular contents, thereby preventing an inflammatory 
reaction. Endonuclease-mediated breakdown of DNA in apoptosis 
leads to the generation of multiples of 180 to 200 base pair 
fragments. Programmed myocyte cell death is the prevailing form 
of myocardial damage produced by occlusion of a major epicardial 
coronary artery, whereas necrotic myocytes cell death follows 
apoptosis and contributes minimally to the progressive loss of 
myocytes after infarction (Anversa et al., 1998). The fact that 
apoptosis plays a role in the tissue damage seen after myocardial 
infarction has pathological and therapeutic implications. Because 
apoptosis is a highly regulated process, a better understanding of 
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the circumstances that specifically trigger apoptosis during and 
after myocardial infarction, and a better understanding of the 
cellular mechanism that control apoptosis, could lead to 
therapeutic strategies to limit the amount of tissue damage in 
patients with myocardial infarction. 
 
1.2.4.2 Necrosis 
Necrosis is usually defined in a negative fashion, as a type of cell 
demise that involves rupture of the plasma membrane without the 
hallmarks of apoptosis and without massive autophagic 
vacuolization. The principal features of necrosis include a gain in 
cell volume (oncosis) that finally culminates in rupture of the 
plasma membrane, and the unorganized dismantling of swollen 
organelles. Necrosis is considered to be harmful because it is often 
associated with pathological cell loss which results in an 
inflammatory response (Vakkila and Lotze, 2004). An 
inflammatory response is an important component of ischemia 
injury. An important distinction between necrosis and apoptosis is 
the manner in which DNA is degraded; in necrosis, DNA is 
broken down randomly sized fragments. A typical necrosis 
mechanism involves opening of mitochondrial permeability 
trasition pore (MPTP) in the inner mitochondrial membrane. 
Events during ischemia can contribute to MPTP opening, that 
results in loss of the eletrical potential difference due to the proton 
gradient that normally exists across the inner membrane, and in 
ATP depletion. Cyclophilin D is an important regulator of MPTP; 
cells lacking cyclophilin D are resistant to oxidative stress but 
sensitive to apoptosis stimuli (Whelan et al.). 
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Figure 1.4: Intrinsic and extrinsic cell death pathways in cardiac myocytes. 
In the extrinsic pathway, ligand binding induces death receptors to recruit 
Fas-Associated protein with Death Domain (FADD), which recruits 
procaspase-8. Within this complex (DISC), procaspase-8 dimerizes and is 
activated. Caspase-8 activates procaspase-3, which cleaves cellular proteins 
causing cell death. In the intrinsic pathway, extracellular and intracellular 
stimuli signal to the mitochondrium through a variety of BH3-only proteins 
and through Bax (modified from Foo et al., 2005). 
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1.2.4.3 Autophagy 
In contrast to necrosis and apoptosis, autophagy is primarly a 
survival mechanism. Authophagy is a slow, spatially restricted 
phenomenon in which organelles, proteins, and lipids are 
sequesteres within double-membraned vacuoles and finally 
digested by lysosomal hydrolases (Kroemer and Jaattela, 2005). 
This process provides cells with amino acids, free fatty acids, and 
energy in times of nutrient deprivation. There are studies showing 
that inhibition of autophagy during prolonged ischemia is 
detrimental, suggesting a potential protective role with its function 
in helping cells survive nutrient deprivation (Takagi et al., 2007). 
 
1.2.5 Therapies for ischemic heart disease 
The ideal therapy would have the following activities: it would 
minimize cardiomyocytes loss by reducing cell death, promote 
return of ischemic dysfunctional myocardium to normal function, 
stimulate revascularization of the ischemic region by enhancing 
angiogenesis, and regenerate viable tissue by replacing that lost as 
a consequence of the ischemic event, thereby preserving 
contractile function and reducing the opportunity for scarring. 
Current therapies address the process of heart ischemic failure by 
different approaches: in the acute setting reducing, the duration of 
the ischemia by surgically or pharmacologically removing the 
vascular blockage; in the chronic phase relieving infarcted heart 
work with drugs and devices (Fraser et al., 2004).  
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1.2.5.1 Limitation of the infarct size 
The quantity of myocardium that becomes necrotic as a 
consequence of coronary artery occlusion is determined by factors 
outside the site of the occlusion. While the central zone of the 
infarct contains necrotic tissue that is irretrievably lost, the fate of 
the surrounding ischemic myocardium may be improved by the 
timely restoration of coronary perfusion, reduction of myocardial 
oxygen demand, and prevention of the accumulation of noxious 
metabolites. Up to one-third of patients with STEMI may achieve 
spontaneous reperfusion of the infarct-related coronary artery 
within 24h. Pharmacological treatments (i.e. by fibrinolysis) or 
mechanical revascularization with coronary angioplasty (PCI) 
accelerate the reperfusion through the occluded infarct-related 
artery in those patients in whom spontaneous thrombolysis would 
ultimately have occurred.  
 
1.2.5.2 Pharmacologic therapy 
Angiotensin-converting enzyme inhibitors (ACE-inhibitors) 
decrease afterload by antagonizing the vasopressor effect of 
angiotensin, thereby decreasing the amount of work that the heart 
must perform. It is also believed that angiotensin directly affects 
cardiac remodeling and blocking its activity can consequently 
reduce the deterioration of cardiac function. Diuretics therapy is 
indicated for relief of congestive symptoms. As cardiac frequency 
is the main determinant of myocardial oxygen comsuption, its 
reduction is an important protection strategy against myocardial 
ischemia. β-blockers reduce blood pressure and contractibility, 
and it has been shown they also reduce necrotic area after 
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cornonaric occlusion; the administration of β-blockers can 
decrease mortality and improve left ventricular function (Faxon, 
2004). 
 
1.2.5.3 Angiogenesis 
Angiogenesis is the biologic process of forming new blood 
vessels. Under physiological conditions, angiogenesis is regulated 
by the local balance between endogenous stimulators and 
inhibitors of this process. Both acute and chronic myocardial 
ischemia have been clearly shown to stimulate angiogenesis in 
many experimental models. Therapeutic angiogenesis stimulates 
the growth of new blood vessels. Traditional coronary 
revascularization therapies such as coronary angioplasty or bypass 
graft surgery act by restoring blood flow through pre-existing 
coronary vessels. One limitation of these approaches may be the 
failure to normalize myocardial perfusion, due to the concomitant 
presence of small resistance vessel disease. In contrast, therapeutic 
angiogenesis is based on the concept that coronary collateral 
development may be stimulated by pharmacological or molecular 
means and can limit myocardial ischemia. 
 
1.2.5.4 Surgical therapy 
Surgery may have a role in ameliorating ischemic heart failure. 
Patients with dysfunctional but viable myocardium (a condition 
named hybernation) and diffuse coronaropathy benefit from 
coronary bypass surgery in terms of ventricular performance and 
prognosis. Further, a viable option for severe remodeling due to 
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large scars is ventricular cardiomyoplasty, although long-term 
benefits have been recently challenged.  
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1.3 P2 RECEPTORS IN THE CARDIOVASCULAR 
SYSTEM 
 
In the cardiovascular system, evidence is accumulating to indicate 
that P2 receptors mediate important physiologic effects, including 
vasoconstriction and vasodilatation, growth of vascular smooth 
muscle and endothelial cells, angiogenesis, vascular remodelling, 
coagulation, platelet aggregation, inflammation and several aspects of 
cardiac function. The purinergic system and its receptors are also 
involved in development of myocardial infarction, heart failure and 
xenograft rejection. The physiological effects of the purinergic 
signalling system are dependent on the release of extracellular 
nucleotides, the degradation by ectonucleotides, the type of P2 
receptors expressed on the cells, their desensitisation rates and their 
second messengers. P2 receptors have highly specific organ 
distributions and they can be rapidly up- or downregulated. Among 
the 15 receptor identified subtypes, one (P2Y12) is the target for one 
of the most widely used medical drugs the platelet inhibitor 
Clopidogrel (Plavix) (Erlinge and Burnstock, 2008).  
 
1.3.1 Regulation of vascular tone  
Vasoconstriction produced by ATP released as a cotransmitter with 
noradrenaline (NA) from perivascular sympathetic nerves was 
recognised early (Burnstock, 1976). Later, it was shown that ATP 
acted on endothelial cells to release endothelial derived relaxing 
factor, such as nitric oxide (NO) resulting in vasodilatation 
(Burnstock, 1987). A dual purinergic neural and endothelial control 
of vascular tone was established. The most important contractile 
32 
 
receptors on the vascular smooth muscle cells (VSMC) are the ATP 
P2X1 receptor, the ATP/UTP P2Y2 receptor, the UDP P2Y6 receptor, 
and the ADP P2Y12 receptor  
 
1.3.1.1 Endothelial regulation 
Extracellular nucleotides produce several important effects mediated 
by activation of endothelial cells. Shear stress and hypoxia are 
important stimuli for both ATP and UTP release from endothelial 
cells (Burnstock, 1987). Both of them reduce forearmvascular 
resistance in a prostaglandin and NO independent way 
(Hrafnkelsdottir et al., 2001), indicating an important role for 
endothelium-derived hyperpolarising factor in P2 receptor-mediated 
vasodilatation in man. The P2Y1 receptor seems to be of major 
importance in most vascular beds (Erlinge et al., 1998). P2Y2 and to a 
lesser degree P2Y6 are also important endothelial P2Y receptors 
(Wang et al., 2002). Extracellular ATP in the circulation is rapidly 
degraded into ADP, AMP and adenosine by ectonucleotidases. 
Vascular NTPDase1 (CD39) is an endothelial cell membrane protein 
with both ecto-ATPase and ecto-ADPase activities (Kaczmarek et al., 
1996). Ectonucleotidases are also released by shear stress from 
endothelial cells (Yegutkin et al., 2000). Reactive hyperaemia is the 
massive increase in blood flow that starts when a blood vessel is 
opened after a period of ischaemia. It has been proposed that different 
purines may mediate three phases of the reactive hyperaemia 
(Olivecrona et al., 2004). According to this hypothesis, ATP would 
mediate the first part of the hyperaemia via endothelial P2Y2 or P2X4 
receptors. ATP would then be degraded to ADP, which mediates peak 
hyperaemia via endothelial P2Y1 receptors, followed by degradation 
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of ADP to adenosine resulting in late phase hyperaemia mediated via 
A2a receptors on smooth muscle cells. 
 
1.3.1.2 Red blood cells as regulators of vascular tone 
Blood flow increases in response to decreased tissue oxygen levels. 
Red blood cells (RBCs) contain millimolar amounts of ATP and 
possess the membrane-bound glycolytic enzymes necessary for its 
production (Bergfeld and Forrester, 1992). ATP is released in 
response to reductions in oxygen tension and pH (Ellsworth et al., 
1995). It has been shown in vitro that vessels dilate in response to low 
O2 levels only when blood vessels are perfused with RBCs (Dietrich 
et al., 2000). The released ATP then binds to P2Y receptors on the 
endothelium and stimulates vasodilatation. Thus, RBC function as an 
O2 sensor, contributing to the regulation of blood flow and O2 
delivery, by releasing ATP depending on the oxygenation state of 
haemoglobin. ADP activates a negative feedback pathway for ATP 
release from human RBCs via P2Y13 receptors (Wang et al., 2005). 
Since blood consists of approximately 40% RBCs that contain a 
1,000-fold higher ATP concentration than plasma (mmol/l vs μmol/l), 
even a minor release of ATP from the high intracellular 
concentrations could have major circulatory effects. A negative 
feedback system may therefore be of great physiological importance 
to mitigate ATP release. 
 
1.3.2 Atherosclerosis  
Atherosclerosis is the main cause of ischaemic stroke and 
cardiovascular disease and is now considered to be an inflammatory 
disease (Hansson, 2005). Evidence both from basic research and from 
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clinical studies indicates important involvement for purinergic 
signalling in the atherosclerotic process at several levels. 
 
1.3.2.1 Atherosclerosis-P2 receptor-mediated effects on 
inflammatory cells 
Inflammatory cells express a large number of P2 receptors with 
multiple effects (Di Virgilio et al., 2001). The final result is difficult 
to predict depending on the subtype of receptor expressed by a 
particular cell type and on the differentiation stage of the cell. The 
most important inflammatory cells for atherosclerosis are monocytes 
that differentiate into macrophages or dendritic cells in the plaque, 
and the T-helper and suppressor lymphocytes that coordinate the 
inflammatory reaction in the plaque (Hansson, 2005). P2X7, P2Y2 and 
P2Y11 receptors have been suggested to be important players in 
atherosclerosis (Di Virgilio and Solini, 2002). The P2X7 receptor is 
mitogenic and anti-apoptotic for T lymphocytes (Kawamura et al., 
2005), is important for release of interleukin (IL)-1 (Ferrari et al., 
1997), tumour necrosis factor (Suzuki et al., 2004) and L-selectin, an 
adhesion molecule important for lymphocyte binding to endothelium 
(Gu et al., 1998). All of these effects are known to be important for 
atherosclerosis development. ATP and UTP are chemotactic for 
dendritic cells probably via the P2Y2 receptor and may attract 
inflammatory cells to the vascular lesion (Idzko et al., 2002). The 
P2Y2 receptor enhances the oxidative burst in human macrophages 
(Schmid-Antomarchi et al., 1997). A polymorphism (G-459-A) in the 
P2Y11 receptor has been shown to have clinical importance by 
increasing the risk of acute myocardial infarction (AMI) (Amisten et 
al., 2007). The G-459-A, carried by one fifth of the population, 
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causes an Ala-87-Thr substitution in the P2Y11 ATP receptor and 
increases the risk of myocardial infarction by 21%. The mechanism 
by which the polymorphism causes AMI seems to be coupled to 
increased inflammation because the Thr-87 variant of the P2Y11 
receptor was coupled to elevated C-reactive protein (CRP) levels. 
CRP is a marker of inflammation and an independent prognostic risk 
factor for the development of AMI (Hansson, 2005). ATP acting on 
P2Y11 receptor regulates the maturation of human monocyte-derived 
dendritic cells and induces immunosuppression by inhibiting T-helper 
cytokines and promoting T-helper 2 cytokines (Kaufmann et al., 
2005). P2Y11 receptor is important in the development of 
atherosclerosis via modulation of inflammation either via effects on T 
lymphocytes or macrophages cells. UTP and ATP stimulate 
expression of proinflammatory vascular cell adhesion molecule-1 
(VCAM-1) in endothelial cells through activation of the P2Y2 
receptor and increase the adherence of monocytic cells to human 
coronary endothelial cells, an effect that is inhibited by anti-VCAM-1 
antibodies (Seye et al., 2003). VCAM is important for the recruitment 
of monocytes and lymphocytes. In conclusion, ATP and UTP 
stimulate several inflammatory responses known to be important for 
atherosclerosis development. 
 
1.3.3 Heart 
Adenine nucleotides are continually present in quite variable amounts 
in the extracellular space of the heart. ATP is released in the heart as 
a cotransmitter together with catecholamines from sympathetic 
nerves, but it may also be released from other sources in the heart 
such as endothelium, platelets, RBCs and ischaemic myocardium 
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(Vassort, 2001). P2 receptors are abundantly expressed in the foetal 
human heart (Bogdanov et al., 1998) as well as in the adult human 
heart of both healthy subjects and patients with heart disease (Banfi et 
al., 2005; Vassort, 2001). 
 
1.3.3.1 Inotropy  
In cardiomyocytes, ATP stimulates a pronounced positive inotropic 
effect and may also act in synergy with β-adrenergic agonists to 
augment myocyte contractility (Danziger et al., 1988; Vassort, 2001; 
Zheng et al., 1996) ATP stimulates an increase in cytosolic calcium 
and evidence for the involvement of inositol 1,4,5-trisphosphate 
(IP3)-coupled P2Y2 receptors and ion channel P2X receptors has been 
presented (Mei and Liang, 2001; Podrasky et al., 1997; Scamps and 
Vassort, 1994). The inotropic effects of ATP are dependent on both 
IP3 and cAMP (Balogh et al., 2005). Catecholamines act on β-
receptors and mediate their inotropic effect by an increase of cAMP; 
antagonists of these receptors are important drugs for the treatment of 
hypertension and reduce mortality in congestive heart failure. UTP 
has been shown to induce a positive inotropic effect in rat atria and in 
rat and guinea pig ventricular cardiomyocytes (Froldi et al., 1994; 
Froldi et al., 2001). Stable UTP and UDP analogues induce a 
pronounced inotropic effect on mouse cardiomyocytes (Wihlborg et 
al., 2006). The P2Y2 receptor is the most abundantly expressed 
receptor with very low levels of the P2Y4 receptor in the human heart, 
suggesting that the inotropic effects of UTP are mediated via P2Y2 
receptors, while the UDP effects are mediated via the P2Y6 receptor 
(Wihlborg et al., 2006). These mechanisms are mediated via IP3-
mediated signalling. P2X receptors are probably also involved, since 
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several subtypes are expressed, but it has not been possible to 
perform a clear receptor characterisation due to lack of selective 
antagonists. 
 
1.3.3.2 Myocardial infarction 
Using microdialysis, ATP in the interstitial space has been estimated 
to be around 40 nmol/l, but the levels may increase markedly during 
electrical stimulation, ischaemia, challenge with cardiotonic agents, 
increase in blood flow, mechanical stretch and increased work load 
(Vassort, 2001). ATP is released from cardiomyocytes during 
reduced oxygen tension and both UTP and ATP are released from the 
heart during cardiac ischaemia (Erlinge et al., 2005). It is noteworthy 
that patients with myocardial infarction have higher plasma levels of 
both ATP and UTP (Borna et al., 2005; Wihlborg et al., 2006). There 
is a significant increase in ectonucleotidase activity (NTPDase1) in 
the hearts of patients with ischaemic heart disease (Kittel et al., 2005) 
that could represent a compensatory mechanism against increased 
nucleotide levels during chronic ischaemia. An interesting yin and 
yang situation for ATP and UTP has been revealed regarding 
hypertrophic effects: UTP, but not ATP, causes hypertrophic growth 
in neonatal cardiomyocytes (Figure 1.5) (Zheng et al., 1994). In 
contrast, ATP inhibits hypertrophy and may even induce apoptosis 
and necrosis (Mazzola et al., 2008). Both UTP and ATP transactivate 
epidermal growth factor receptors, but only ATP stimulates the 
hypertrophic marker genes atrial natriuretic peptide and myosin light 
chain 2 (Morris et al., 2004). Similarly, UTP but not ATP protects 
cultured cardiomyocytes against hypoxic stress (Yitzhaki et al., 
2005). Since UTP is released during preconditioning (Erlinge et al., 
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2005), a role for this nucleotide in the protective effects of 
preconditioning is plausible. Recently, Yitzhaki and co-workers were 
able to demonstrate prominent reductions in myocardial infarction 
size and improved rat heart function in vivo, by a single intravenous 
bolus dose of UTP before ischaemia (Yitzhaki et al., 2005) (Figure 
1.5). 
 
1.3.3.3 Congestive heart failure 
There are several reports of alterations or adaptations of purinergic 
signalling during congestive heart failure. The positive inotropic 
effect of ATP is impaired in heart failure, but reversed by the 
angiotensin-converting enzyme inhibitor imidapril (Saini et al., 
2005). The contractile responses for the P2Y11 receptor agonist AR-
C67085 are decreased in heart failure, suggesting a downregulation of 
this receptor function in cardiomyocytes in a similar manner as seen 
for β1-receptors in congestive heart failure (Balogh et al., 2005). In 
human hearts, only the P2X6 receptor was altered in congestive heart 
failure (Banfi et al., 2005). In congestive heart failure, P2X1 receptor 
is downregulated in VSMC in resistance arteries, which could 
represent a protective response against the increased sympathetic 
nerve activity and peripheral resistance seen in congestive heart 
failure (Malmsjo et al., 1999). Several P2 receptors have been 
suggested as targets for pharmacological treatment of congestive 
heart failure. Overexpression of P2X4 receptors has a beneficial, 
lifeprolonging effect in a heart failure model (Yang et al., 2004). The 
extracellular pyrimidines UTP and UDP may be inotropic factors in 
man, acting on P2Y2 and P2Y6 receptors stimulating the same 
intracellular pathways as angiotensin II. Synthetic agonists could thus 
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be used as inotropic agents during circulatory shock and antagonists 
may have effects similar to angiotensin II receptor blockers, being 
beneficial in the treatment of hypertension and congestive heart 
failure (Erlinge and Burnstock, 2008).  
 
 
 
Figure 1.5: Functional role of purines and pyrimidines acting on P2 
receptor in the regulation of the heart 
ATP, UTP and UDP exert inotropic effects on cardiomyocytes leading to 
increased cardiac output. UTP and UDP stimulate hypertrophy of 
cardiomyocytes, while ATP can have apoptotic effects. UTP protects against 
ischaemic injury and cardiomyocyte cell death (modified from Erlinge and 
Burnstock, 2008). 
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1.3.4 Platelets 
ADP, released from erythrocytes or produced after ectonucleotidase 
breakdown of ATP released from erythrocytes and endothelial cells, 
was found to cause platelet aggregation as early as in 1961, before the 
concept of P2 receptors was conceived (Gaarder et al., 1961). Two 
ADP receptors (P2Y12 and P2Y1) and one ion channel ATP receptor 
(P2X1) are expressed on platelets (Kunapuli et al., 2003). The P2Y12 
receptor is coupled to inhibition of cAMP. The molecular 
identifications of the P2Y12 receptor and generation of knockout mice 
revealed highly prolonged bleeding times in the absence of P2Y12; the 
platelets of these mice aggregated poorly in response to ADP and 
displayed a reduced sensitivity to thrombin and collagen (Foster et 
al., 2001). The P2Y1 receptor is responsible for ADP-induced shape 
change and weak, transient aggregation, while the P2Y12 receptor is 
responsible for the completion and amplification of the response to 
ADP and to all platelet agonists, including thromboxane A2, 
thrombin and collagen. A synergistic interaction  between ATP and 
NA in stimulating platelet aggregation may have significant clinical 
implications and suggests a prothrombotic role for ATP in stress 
(Birk et al., 2003). ADP acting on P2Y12 receptors is not only 
important for platelet activation, but also stimulates vasoconstriction. 
Stable drugs with antagonistic effects on P2Y12 receptors, affecting 
both platelets and VSMC, could be of double therapeutic benefit in 
their prevention of both thrombosis and vasospasm (Wihlborg et al., 
2004). 
 
 
1.3.4.1 Coagulation 
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The prothrombotic effect of ADP on the platelets is counteracted by 
the effects of UTP and ATP on the endothelium that stimulate 
substained release of tissue-type plasminogen activator (tPA) with 
fibrinolytic effects (Hrafnkelsdottir et al., 2001). ATP also releases 
plasminogen activator inhibitor (PAI-1) which, in turn, inhibits tPA 
(Bouchie et al., 2000). Thus, P2 receptors are involved in several 
stages of haemostasis, which is important for the development of 
atherosclerosis and thrombotic occlusions leading to myocardial 
infarction and stroke. The first ADP inhibitors, ticlopidine and 
clopidogrel, were developed before the cloning and identification of 
the platelet ADP receptors. Later, it was concluded that they were 
prodrugs, converted in the liver to a metabolite that binds irreversibly 
to the P2Y12 receptor resulting in non-competitive antagonism. 
Ticlodipine has the disadvantage of a small risk of neutropaenia, so 
clinically so far the most important contribution of drug development 
aimed at P2 receptors has been the beneficial effects of the platelet 
ADP receptor antagonist Clopidogrel in atherosclerotic disease. In the 
CAPRIE trial, Clopidogrel was even more effective compared to 
aspirin in preventing myocardial infarctions (Logman et al., 2010). 
Clopidogrel, in addition to aspirin, turned out to be necessary to 
prevent acute in-stent thrombosis in percutaneous coronary 
interventions. The CURE trial demonstrated that the addition of 
clopidogrel to aspirin reduced clinical events by 20% in acute 
coronary syndromes (Mehta et al., 2001). This has also been shown 
for ST-elevation myocardial infarctions (COMMIT and CLARITY 
trials) (Berg et al., 2007). However, long-term secondary prevention 
in high-risk groups with clopidogrel added to aspirin did not have 
significant benefits (CHARISMA trial) (Berger et al., 2010). 
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Clopidogrel is a rather weak antagonist at P2Y12 receptors with 
variable effects, often referred to as clopidogrel resistance. Newer, 
P2Y12 receptor antagonists, such as prasugrel and AZD6140 
(Ticangrelor), have a stronger and more consistent effect and are 
currently being studied in major clinical trials (TRITON and 
PLATO)(Serebruany et al.,2010). Clopidogrel is one of the most 
prescribed drugs in the world for the treatment of thrombosis, stroke 
and myocardial infarctions in millions of patients. Due to its patent 
expiration in 2011, it is believed that the new drugs under 
development will take part of its market starting from that date.  
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
2 
AIM OF STUDY 
 
 
 
 
 
 
 
 
It is now widely accepted that, in addion to functioning as 
intracellular energy source, extracellular nucleotides initiate a wide 
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range of intracellular signalling cascades through the activation of a 
plethora of purinergic receptors. The purines and pyrimidines ATP, 
adenosine diphosphate (ADP), uridine triphosphate (UTP), uridine 
diphosphate (UDP), and, as more recently recognized, sugar 
nucleotides like UDP-glucose and UDP-galactose (Abbracchio et al., 
2006; Burnstock, 1997) act on various P2X homo- and 
heteromultimer ionotropic receptors and on 8 P2Y metabotropic 
receptor subtypes (Ralevic and Burnstock, 1998). In the 
cardiovascular system, evidence is accumulating to indicate that P2 
receptors mediate important physiologic effects, including 
vasoconstriction and vasodilatation, growth of vascular smooth 
muscle and endothelial cells, angiogenesis, vascular remodelling, 
coagulation, platelet aggregation, inflammation and several aspects of 
cardiac function. The purinergic system and its receptors are also 
involved in development of myocardial infarction, heart failure and 
xenograft rejection (Erlinge and Burnstock, 2008; Vassort, 2001). 
The normal basal levels of plasma and interstitial ATP are very low 
and do not exceed 20-40 nM in human venous plasma and in the 
cardiac interstitial space. Hypoxia and ischemia induce ATP release 
into the cardiac interstitial space from purinergic nerves innervating 
the heart, cardiac vascular endothelial cells and cardiomyocytes. ATP 
is also released from the cytoplasmatic pool under these conditions. 
In cardiomyocytes cells, ATP acting through P2Y and P2X receptors 
stimulates a pronounced positive inotropic effect and may also act in 
synergy with ß-adrenergic agonists to augment myocyte contractility. 
In addition, potent effects may be exerted by nucleotides on 
cardiomyocytes viability, under both physiological conditions and 
after hypoxia, when cardiomyocytes themselves release massive 
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amount of ATP, mainly by extrusion via the maxi-anion channel 
(Dutta et al., 2008). In the last years, we have investigated the effects 
of both adenine and uracil nucleotides on the viability of HL-1 
cardiomyocytes, the only available cell line that spontaneously 
contracts in vitro and maintains a differentiated cardiac phenotype. 
We showed that murine HL-1 cardiomyocytes express a wide panel 
of P2X and P2Y receptors known that either exclusively respond to 
adenine nucleotides (P2X receptors), to both adenine and uracil 
nucleotides (P2Y2, P2Y4, P2Y6) or to sugar nucleotides (P2Y14 
receptor). We demonstrated that the exposure of cardiomyocytes to 
high concentrations of adenine nucleotides (ATP, ADP or BzATP) 
induces cardiomyocyte cell death through a mechanism involving 
both P2Y and P2X receptors (Mazzola et al., 2008). However, in that 
study the specific P2 receptors involved were not identified. It would 
be very interesting to study the role of specific P2 receptor in the cell 
death associated to cardiac ischemia. On this basis, a first aim of the 
present study has been to set up and characterize a suitable 
ischemic/hypoxic protocol of cardiomyocyte ischemia in HL-1 cells. 
A second goal of this study has been to assess if ATP is released from 
these cells after an ischemic/hypoxic stress. A third goal has been to 
establish whether specific P2 receptors play a role in the cell death 
associated to cardiomyocyte ischemic/hypoxic stress. To do so we 
have taken advantage of both pharmacological agents and of silencing 
techniques via small interfering RNAs.  
  
 
 
 
 
 
 
3 
MATERIALS AND 
METHODS 
 
 
 
 
 
 
 
3.1 Cell culture  
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HL-1 cells, a cardiac muscle cell line derived from the AT-1 
mouse atrial myocyte tumor lineage, were a kind gift from 
William C. Claycomb, Ph.D. (Professor of Biochemistry and 
Molecular Biology, Louisiana State University Health Sciences 
Center, New Orleans, Louisiana). HL-1 cells are currently the only 
available cardiomyocyte cell line that continuously divides and 
spontaneously contracts while maintaining a differentiated cardiac 
phenotype. Cell were cultured in complete Claycomb medium 
supplemented with 10% foetal calf serum (FCS) and 
Norepinephrine (100 µM), following Professor Claycomb’s 
instructions. (White et al., 2004). They were used for experiments 
when approximately 70 to 80% confluent. 
 
3.1.1 Treatment of cell 
In separate experimental groups, cells received no intervention 
(normoxia control, 95% air and 5% CO2) or were exposed to 
ischemic/hypoxic stress. Hypoxia was produced by exposure to 
5% CO2 and 95% N2 in a modular incubator chamber (Billups-
Rothenberg) for 16 h in the presence of serum- and glucose-free 
Dulbecco's Modified Eagle Medium (DMEM). Pyridoxal-
phosphate-6-azophenyl-2´,4´-disulfonate (PPADS, 100 μmol/L; 
suramin (100 μmol/L); gadolinium (III) chloride (GdCl3 100 
μmol/L); 2′,3′-O-(2,4,6-Trinitrophenyl) adenosine 5′-triphosphate 
monolithium trisodium salt (TNP-ATP, 10 μmol/L); 4-[(2S)-2-[(5-
isoquinolinylsulfonyl)methylamino]-3-oxo-3-(4-phenyl-1 
piperazinyl)propyl] phenyl isoquinolinesulfonic acid ester (KN-
62, 10 μmol/L); (5-[[5-3,4-dihydro-2-oxo-4-thioxo-1(2H)-
pyrimidinyl]methyl]-N-[1Htetrazol-5-yl]-2-furancarboxamide 
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(AR-C118925, kind gift from Prof. C.E. Muller); N,N''-1,4-
butanediylbis[N'-(3-isothiocyanatophenyl) thiourea (MRS2578 1-
10 μmol/L); apyrase (30 U/mL); pertussis toxin (PTX, 100 
nmol/L); GF 109203X (10 μmol/L, Sigma-Aldrich); guanosine 5′-
[β-thio]diphosphate trilithium salt (GDP β-s 5 μmol/L), were all 
added to cultures 1 h before hypoxia. 
 
3.2 Real-time reverse transcription polymerase chain reaction 
Total cell RNA was extracted using TRIzol Reagent and reverse 
transcribed at 42°C for 50 min and 70°C for 15 min (Perkin-Elmer 
Life Sciences, Milano, Italy). For 1 μg of total cell RNA, we used 
200 units of reverse transcriptase (RT; SuperScript II, Invitrogen, 
Life Technologies, Milano, Italy), 3 μg of random hexamers 
primers, 1 mmol/L of dNTPs and 40 units of Rnase inhibitor. 
Real-time quantitative polymerase chain reaction (PCR) was then 
carried out to detect P2Y2, P2Y4, P2Y6, and P2X7 mRNA. 18S 
rRNA was used for sample .  
The sequences of the primers used were:  
 P2Y6 sense: 5´- CCC AAC CTG CCT TGA AAA CA-3´, 
 P2Y6 antisense: 5´- TCG GAG AGT CTG TCT CAT GCA 
A-3´;  
 18S sense: 5'-CGGCTACCACATCCAAGGAA-3';  
 18S antisense: 5'-
CCTGTATTGTTATTTTTCGTCACTACCT-3'. 
Primers for the detection of P2Y2 (QT00097202), P2Y4 
(QT00266686), and P2X7 (QT00130900) were from Qiagen 
(Milan, Italy). A total of 2.5 μL of cDNAs were incubated in 25 
μL IQ Supermix containing P2Y2, P2Y6, P2X7, or 18S primers and 
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SYBRGreen fluorescence dye (Bio-Rad Laboratories, Milano, 
Italy). Real-time reverse transcription PCR was carried out in 
triplicate for each sample on an iCycler Optical System, Bio-Rad 
Laboratories (Milano, Italy). Amplifications of P2Y4 were 
performed in a GeneAmp 9700 thermal cycler (Applied 
Biosystems) for 30-40 cycles (94°C for 45 s, 45 s at an annealing 
temperature of 51-60°C, 72°C for 45 s), after denaturation at 94°C 
for 2 min. Amplified product was size-separated by 
electrophoresis on a 1.5% agarose gel. 
 
3.3 RNA interference and cell transfection 
Validated high-performance purity grade small interfering RNAs 
(siRNA) against mouse P2Y2 (SI00179235), P2Y4 (SI00217588), 
P2Y6 (SI01367891), and P2X7 (SI00197330) were synthesized by 
QIAGEN (Milan, Italy) using the HiPerformance siRNA design 
algorithm and a proprietary homology analysis tool. Control 
siRNA, with a nonsilencing oligonucleotide sequence that does 
not recognize any known homology to mammalian genes, was 
also generated as a negative control. RNA, dissolved in an 
appropriate volume of RNAase-free water. HL-1 cardiomyocytes, 
at 70-80% confluence, were transfected with siRNA using 
HiPerFect Transfection Reagent (Qiagen, Milan, Italy). After 24 h, 
the transfection procedure was repeated before induction of 
ischemic/hypoxic stress . 
 
 
 
3.4 Nuclear staining of adhering cells 
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After cell treatment, cells were fixed in 4% paraformaldehyde in 
phosphate buffered saline (PBS) and nuclear chromatin stained by 
using the fluorescent dye Hoechst 33258 (Sigma-Aldrich, St. 
Louis, MO, USA). 
 
3.5 Flow cytometric evaluation of apoptosis 
The percentage of necrotic cells in the adhering cells was 
evaluated by means of propidium iodide (PI) staining of DNA 
followed by flow cytometric analysis. When employed at isotonic 
conditions, PI can indeed only permeate cells with damaged 
membranes, thus providing a direct measure of earlier membrane 
events associated to necrosis. Induction of apoptosis was also 
confirmed by measuring the switch out of Annexin V binding to 
phosphatidylserine on outer membrane of apoptotic cells . 
 
3.6 Nucleosome immunoassay 
Photometric enzyme immunoassay for the qualitative and 
quantitative in vitro determination of cytoplasmic histone-
associated DNA fragments (mono- and oligonucleosomes) after 
induced cell death was performed. (Roche Diagnostics GmbH 
Roche Applied Science 68298 Mannheim Germany). 
 
3.7 ATP release assay 
ATP release was assayed by means of the ATP Bioluminescence 
Assay Kit HS II (Roche Diagnostics GmbH Roche Applied 
Science 68298 Mannheim Germany), an ATP monitoring system 
based on firefly (Photinus pyralis) luciferase. The ATP assay 
system is based on the production of light caused by the reaction 
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of ATP with added luciferase and D-luciferin. This is illustrated in 
the following reaction scheme: 
ATP + D-Luciferin + O2 Oxyluciferin +Mg
2++ 
AMP + PPi + 
CO2 + Light. 
The emitted light is proportional to the ATP concentration was 
monitored at 560 nm using a luminometer. 
 
3.8 Statistical analysis 
All results are expressed as mean ± S.E.M. of at least three 
independent experiments. Statistical significance between groups 
was derived using a paired 2-tailed Student’s t test. Differences 
were considered significant when p was less than 0.05. 
 
 
 
 
 
 
 
 
  
 
 
 
 
4 
RESULTS 
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4.1 HL-1 cardiomyocytes express P2 receptors responding to 
both adenine and uracil nucleotides 
As a first step to the characterization of the effects of P2 receptors 
on the viability of HL-1 cells, we assessed the presence of all 
rodent P2 receptors by RT-PCR. Amplification products with the 
expected molecular weight for all known P2X receptors (with the 
only exception of P2X2) and for P2Y2, P2Y4, P2Y6 and P2Y14 
were obtained (Figure 4.1). No specific signals for P2Y1, P2Y12 
and P2Y13 were obtained; negative data were not due to technical 
problems, since specific amplification products for these receptors 
were detected in murine tissues or cell lines which express these 
receptors here utilized as positive controls (Figure 4.1).  
 
4.2 Ischemic/Hypoxic stress induces ATP release in HL-1 
cardiomyocytes 
Cardiomyocytes release ATP in the extracellular milieu during 
cardiac ischaemia. Released cellular ATP can serve as a paracrine 
signaling molecule for intercellular communication, or can act in 
an autocrine manner to regulate cellular functions, including those 
of cardiomyocytes. Cultured HL-1 cardiomyocytes exhibited a 
basal release of ATP that was significantly increased at 30 minutes 
after the induction of an ischemic/hypoxic stress (mean increase of 
63.6% ± 9.7; p< 0.005, n=3 from 3 independent experiments, 
Figure 4.2A). To ensure that, at this time point, membrane damage 
did not contribute to ATP release, we analyzed the conditioned 
media from ischemic/hypoxic cells for the presence of the 
cytosolic enzyme lactate dehydrogenase (LDH), a marker of 
cellular damage. We consistently found that ischemic/hypoxic-
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induced ATP release occurred in the absence of LDH release, 
hence with no significant membrane damage compared with 
normoxic controls, suggesting that, at this early stage of hypoxia, 
ATP does not derive from cell necrosis but from release via 
transmembrane channels/pumps.  
 
4.3 Ischemic/hypoxic stress promotes apoptosis of HL-1 
cardiomyocytes 
Ischemic/hypoxic stress induced significant increases in the 
appearance of HL-1 cardiomyocytes apoptosis, as assessed by two 
complementary assays including annexin V and nucleosomal 
immunoassay. An increased number of annexin-positive 
cardiomyocytes was registered after 16 hours of exposure to 
ischemic/hypoxic stress (Figure 4.2B). We found that, at this time 
after ischemic/hypoxic stress induction, the number of propidium 
iodide-positive cells was also increased compared to control value 
(+72.2 % ± 9.9, p <0.005). To confirm the membrane-related 
changes associated with apoptosis, we performed nucleosomal 
ELISA assay, which detects later stages of apoptosis (i.e., 
internucleosomal DNA cleavage). ELISA analysis showed a 
strong increase in the apoptotic index, up to 320.9 % ± 15.8 of 
control value at 16 h (Figure 4.2C). 
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Figure 4.1: HL-1 cardiomyocytes express P2X1,3,4,5,6,7 and P2Y2,4,6,14. The 
presence of P2 receptors was assessed using ad hoc designed RT-PCR 
primers for all cloned murine P2 receptors. For each receptor, amplification 
products in parallel with MW standards are reported. Various tissues or cell 
lines were analysed in parallel as a positive controls: trigeminal ganglia for 
P2X2 and P2X3, total brain for P2X1, P2X4, P2X5, P2X7, P2Y13 and P2Y14, 
heart for P2X6, liver for P2Y4, lung for P2Y2 and N9 cells for P2Y1, P2Y6 and 
P2Y12.  
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Figure 4.2: Ischemia/hypoxia induces release of ATP and promotes 
cardiomyocytes apoptosis: ATP is released by HL-1 cells very early during 
hypoxia, which induces apoptosis. A, HL-1 cells were exposed to normoxia or 
hypoxia for 30 minutes; at the end of the incubation, ATP was measured in 
the conditioned medium. Results are the mean  S.E.M., n=4, *p<0.05, 
Student “t” test. B, C, HL-1 cells were exposed to normoxia or hypoxia for 
16 hours. At the end of the incubation, apoptotic cells were quantified by flow 
cytometric analysis as annexin V positive cells (B) or by immunoenzymatic 
determination of mono/oligonucleosome released in the cultured medium (C). 
Results are the mean  S.E.M. from six separate experiments performed in 
triplicate. *p< 0.05, $ p<0.01 versus normoxic controls, Student “t” test.  
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4.3.1 Morphological features of apoptosis  
Because one important sign of apoptosis is the appearance of 
specific morphological changes, including nuclear condensation 
and chromatin fragmentation, we used Hoechst 33258, a 
fluorescent DNA-binding dye, to stain nuclear chromatin in HL-1 
cardiomyocytes, and examined cell morphology by phase-contrast 
microscopy. Figure 4.3A and 4.3B show the phase contrast 
morphology of HL-1 cardiomyocytes exposed to normoxia or to 
ischemic/hypoxic stress. Control cultures have normal cell bodies 
and intact features with nuclei homogeneous in size and shape and 
very lightly stained with Hoechst 33258 (Figure 4.3A). However, 
when HL-1 cardiomyocytes were exposed to ischemia/hypoxia in 
a glucose-free medium for 16 h, we noticed morphologic 
alterations typical of cells undergoing apoptosis, which became 
rounded and condensed and lost adhesion from the monolayer. 
Furthermore, HL-1 cells displayed condensed chromatin that was 
brightly and uniformly stained by Hoechst 33258 and ranged in 
shape from a single uniform sphere to a collection of multiple 
chromatin dots typical of fragmented apoptotic nuclei (Figure 
4.3B).  
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Figure 4.3: Cardiomyocytes show typical features of apoptosis: A and B 
show representative images of HL-1 cells exposed to either normoxia or 
hypoxia for 16 h. Upper immages are phase-contrast micrographs; lower 
images refer to cultures stained with Hoechst 33,258. Under control 
conditions (A), HL-1 cells morphology appeared normal and cell density was 
approaching confluence. After exposure to ischemia/hypoxia in a glucose-
free medium (B), many of the cells became rounded, showed condensed 
nuclei and detached from the culture dish. 
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4.4 Effect of apyrase on ischemia/hypoxia-induced release of 
ATP and on cardiomyocyte apoptosis 
Endogenously released ATP plays an important role in mediating 
HL-1 cardiomyocytes apoptosis, as treatment with apyrase, a 
nucleotidase that degrades nucleotide triphosphates into nucleotide 
monophosphates and thus completely abolishes the amount of 
ATP released in the medium during ischemia/hypoxia stress 
(Figure 4.4A), significantly prevented the induction of apoptosis 
(Figure 4.4B). Since there is, as expected, a basal release of ATP 
even in the absence of hypoxia, apyrase also significantly reduced 
basal ATP levels during normoxia (Figure 4.4A), but this was not 
associated to any change in cell viability, to confirm that, under 
control conditions, ATP does not mediate cell death.  
 
4.5 Effect of the maxi-anion channel inhibitor GdCl3 on 
ischemia/hypoxia-induced cardiomyocyte apoptosis 
In rat cardiomyocytes, ATP release is mainly mediated by the 
maxi-anion channel under ischemic or hypotonic conditions (Dutta 
et al., 2004). Based on these findings, we reasoned that 
ischemic/hypoxic stress may lead to ATP release from HL-1 
cardiomyocytes through similar mechanisms. To examine this 
possibility, HL-1 cells were treated with the maxi-anion channel 
blocker GdCl3. Treatment of cells with GdCl3 completely 
prevented the induction of apoptosis induced by ischemic/hypoxia 
stress (Figure 4.5).  
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Figure 4.4: Apyrase inhibits ATP release and protects cardiomyocytes 
against cell death during ischemic/hypoxia period A, Apyrase [30U/ml] was 
added to HL-1 cells immediately before normoxia (N) or hypoxia (H). After 
30 min, ATP was measured in the medium. Results are the mean  S.E.M., 
n=3, *p<0.05, Student “t” test. B, Apyrase [30U/ml] was added to cells 
immediately before a 16 h hypoxia (H). Parallel samples received apyrase 
under the same conditions and were maintained for 16 h under normoxic 
conditions (N). Control cells received vehicle. At the end of the incubation, 
enrichment of mono/oligonucleosome in cells was determined by ELISA 
assay. Values are the mean ± S.E.M. from 3 independent experiments run in 
triplicate; *p<0.05 versus corresponding untreated values, Student “t” 
test.#: p< 0.05 versus normoxia untreated cell Student “t” test. N, normoxia; 
H, hypoxia; H-N, values from hypoxia minus values from normoxia. 
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Figure 4.5: GdCl3 protects cardiomyocytes against cell death during 
ischemic/hypoxia period  
GdCl3 (100µmol/L) was added to HL-1 cells 1 hr before normoxia or 
hypoxia. Hystograms report apoptosis under hypoxic conditions after 
subtracting the apoptosis value detected under normoxic conditions. At the 
end of the incubation, enrichment of mono/oligonucleosome in cells was 
determined by ELISA assay. Values are the mean ± S.E.M. from 3 
independent experiments run in triplicate; $: p<0.01 versus corresponding 
control value (vehicle), Student “t” test 
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4.6 ATP treatment induces HL-1 cardiomyocyte apoptosis  
To further confirm the role of released ATP in the induction of 
apoptosis by ischemia/hypoxia in HL-1 cells, we treated 
cardiomyocytes with different concentrations of ATP. We found 
that stimulation of HL-1 cardiomyocytes by ATP itself for 24 h at 
250-500 mol/L increased apoptosis up to 254% ± 37 of control 
values set to 100% (Figure 4.6). 
 
4.7 P2 receptors antagonists prevent the appearance of HL-1 
cardiomyocyte apoptosis induced by ischemia/hypoxia 
We have previously shown that HL-1 cardiomyocytes express all 
known P2X receptors (except for P2X2), as well as the P2Y2,4,6,14 
subtypes (Figure 4.1). To verify if the apoptotic effect of the 
ischemic/hypoxic stress was actually due to activation of P2 
receptors by ATP or other nucleotides released during hypoxia, 
HL-1 cardiomyocytes were exposed to ischemic/hypoxic stress in 
the presence of non selective P2 receptor antagonists, such as 
PPADS and suramin. These treatments almost completely 
prevented the appearance of apoptosis (-82.7% ± 7.7 after PPADS; 
-68% ± 12 after suramin) (Figure 4.7). Because PPADS 
antagonises P2X1,2,3,5 and P2Y4,6, whereas suramin effectively 
blocks P2X1,2,3,5 and P2Y2,6,11, these data suggest that both P2X 
and P2Y receptors contribute to the cardiomyocytic apoptosis 
induced by ischemia/hypoxia. However, since P2X receptors can 
form heteromers characterized by different and unpredictable 
pharmacological profiles, a definite conclusion regarding the 
specific receptor subtypes involved cannot be drawn from these 
data. 
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Figure 4.6: ATP itself induces apoptosis. HL-1 cells were treated with either 
vehicle (Control) or ATP at the indicated concentrations for 24 h. At the end 
of the incubation, enrichment of mono/oligonucleosome in cells was 
determined by ELISA assay. Results are the mean ± S.E.M. from 3 
independent experiments run in triplicate; *p<0.05 versus control untreated 
value, Student “t” test. 
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Figure 4.7: The non selective P2X/P2Y receptor antagonists PPADS and 
Suramin protect HL-1 cardiomyocytes from induction of apoptosis after 
ischemic hypoxia. PPADS (pyridoxal-phosphate-6-azophenyl-2′,4′-
disulfonate, 100µmol/L) and suramin (100µmol/L) were added to cells 1 h 
before normoxia or  hypoxia. After 16 h, enrichment of 
mono/oligonucleosome in cells was determinated by ELISA assay. Values 
represent changes with respect to apoptosis found in control (vehicle) 
hypoxic cells set to 100% and are the mean ± S.E.M. of  3 independent 
experiments run in triplicate. *:p< 0.05 versus corresponding control, 
Student “t” test. H= apoptosis value under hypoxic conditions after 
subtraction of the apoptosis value detected under normoxic conditions. 
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4.8 Inhibition of P2X7 partially prevents the ischemia/hypoxia-
induced apoptosis 
Pre-treatment of cells with 2′,3′-O-(2,4,6-Trinitrophenyl) 
adenosine 5′-triphosphate monolithium trisodium salt (TNP-ATP), 
an antagonist for P2X1–4 receptors, failed to significantly prevent 
the appearance of apoptosis induced by ischemic/hypoxic stress 
(Figure 4.8), thus ruling out a role for these P2X receptor subtypes 
in our model. By contrast, when the specific P2X7 antagonist KN-
62 was tested, a significant reduction of apoptosis in the 
ischemic/hypoxic condition was monitored (Figure 4.8). In order 
to validate the effect of the P2X7 antagonist, we silenced the 
expression of P2X7 receptor using small interfering (si) RNAs 
specifically designed to knock down this receptor subtype. 
Treatment of HL-1 cells with a P2X7 receptor siRNA construct 
reduced the P2X7 receptor mRNA levels by 54% ±3.4 (Figure 
4.9A). The decrease in P2X7 receptor expression resulted in a 
partial, albeit statistically significant, inhibition of apoptosis in 
response to the ischemic/hypoxic stress (-34%± 2.7) (Figure 
4.9B). Taken together, these results point to a possible 
contribution of the P2X7 receptor in the apoptosis in HL-1 
cardiomyocytes induced by ischemia/hypoxia. 
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Figure 4.8: Inhibition of P2X7, but not of P2X1-4 receptors, prevents HL-1 
cardiomyocyte apoptosis induced by hypoxia TNP-ATP (10µmol/L) or KN-
62 (1µmol/L) were added to cells 1 h before normoxia or hypoxia. After 16 h, 
enrichment of mono/oligonucleosome in cells was determined by ELISA. 
Values represent changes with respect to apoptosis found in control (vehicle) 
hypoxic cells set to 100% and are the mean ± S.E.M. from 4 independent 
experiments run in triplicate; $: p<0.01 versus corresponding control values, 
Student “t” test. H= apoptosis value under hypoxic conditions after 
subtraction of the apoptosis value detected under normoxic conditions. 
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Figure 4.9: Gene silencing of P2X7 prevents HL-1 cardiomyocyte apoptosis 
induced by hypoxia A, mRNA analysis of P2X7 by qRT-PCR in HL-1 cells 
transfected with ineffective (negative) siRNA or with P2X7 siRNA. B, HL-1 
cells transfected with ineffective (negative) siRNA or with P2X7 siRNA were 
exposed to normoxia or hypoxia for 16 h for detection of apoptosis. Apoptosis 
values were calculated in hypoxic cells and set to 100%. Values are the mean 
± S.E.M. from 3 independent experiments run in triplicate. *p<0.05 vs. 
negative siRNA-transfected cells, Student “t” test. H= apoptosis value under 
hypoxic conditions after subtraction of the apoptosis value detected under 
normoxic conditions. 
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4.9 Inhibition of P2Y2 prevents ischemia/hypoxia-induced 
apoptosis 
To evaluate the role of P2Y receptor subtypes in the induction of 
apoptosis by the ischemic/hypoxic stress, we used selective P2Y2 
and P2Y6 antagonists. AR-C118925, the only known selective, 
heterocyclic antagonist of the P2Y2 receptor, significantly 
prevented the appearance of apoptosis by -50.8% ± 2 (Figure 
4.10). By contrast, the potent antagonist of P2Y6 nucleotide 
receptor diisothiocyanate derivative MRS2578 did not affect 
hypoxia-induced apoptosis in HL-1 cardiomyocytes (Figure 4.10). 
This pharmacological approach could not be adopted for the P2Y4 
receptor, since no selective antagonists are currently available for 
this receptor subtype. Globally, these pharmacological data 
support a role for P2Y2, but not P2Y6, in hypoxia-induced 
apoptosis. 
In order to validate these results, we adopted a second 
approach based on the use of specific siRNAs against the various 
P2Y receptors. Semi-quantitative real time analysis of P2Y2, and 
P2Y6 mRNAs after transfection of HL-1 cardiomyocytes with 
specific siRNAs showed a reduction of  corresponding receptor 
mRNAs of 70%±6.8 and 89%±3.6, for the P2Y2 and P2Y6 
receptors, respectively (Figure 4.11A and Figure 4.11B). Semi-
quantitative real time analysis could not be performed for the 
P2Y4 receptor in silenced cells, due to the lack of efficacious 
oligonucletide primers for this type of analysis. However, standard 
RT-PCR in cardiomyocytes transfected with P2Y4 siRNA showed 
a dramatic reduction of P2Y4 amplification product at the expected 
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447 pb (see arrow in figure 4.11C) with respect to cells transfected  
with corresponding negative siRNAs.  
In line with the pharmacological data of Figure 4.10, silencing 
of P2Y2 resulted in a marked prevention of apoptosis following 
ischemic/hypoxic stress (Figure 4.12A). No effect was instead 
detected after silencing of P2Y6 (Figure 4.12B). Of interest, gene 
silencing of P2Y4 resulted in a significant increase of cell 
apoptosis during ischemic/hypoxic stress, thus suggesting a 
potential protective role for this receptor (Figure 4.12C).  
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Figure 4.10. Effect of the selective P2Y2 receptor antagonist AR-C118925 
and the selective P2Y6 receptor antagonist MRS2578 on induction of 
cardiomyocyte apoptosis after ischemic hypoxia. AR-C118925 (1-10 µmol/L) 
and MRS2578 (1-10µmol/L) were added to cells 1 h before either normoxia 
or hypoxia. At the end of the 16 h of incubation, apoptosis values were 
determined in hypoxic cells by ELISA assay and set to 100%. Values are the 
mean  ± S.E.M. from 3 individual experiments run in triplicate, *p<0.05 
versus corresponding control values, Student “t” test. H= apoptosis value 
under hypoxic conditions after subtraction of the apoptosis value detected 
under normoxic conditions.  
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Figure 4.11. Gene silencing. of P2Y2, P2Y4, and P2Y6 A, mRNA analysis of 
P2Y2 by quantitative (q) RT-PCR  in HL-1 cells transfected with either 
negative siRNA or with P2Y2 siRNA. B, mRNA analysis of P2Y6 by qRT-PCR 
in HL-1 cells transfected with either negative siRNA or with P2Y6 siRNA 
Values are the means ± S.E.M. of 3 individual experiments run in 
triplicate.*:p< 0.05 versus control siRNA-negative treated cells, Student “t” 
test. C, micrograph showing amplification of P2Y4 mRNA by standard RT-
PCR in HL-1 cells transfected with either negative siRNA or with specific 
P2Y4 siRNA. An amplicon of the expected molecolar weight( see arrow) was 
detected in control cells; this product was marked reduced after silencing. 
Shown are results from one experiment. Similar data have been obtain in 3 
indipendent experimets analysis of P2Y4.  
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Figure 4.12. Effect of P2Y2, P2Y4, and P2Y6 gene silencing on the 
induction of cardiomyocyte apoptosis after ischemic hypoxia. A, HL-1 
cardiomyocytes transfected with either negative siRNA or with  specific P2Y2 
siRNA were exposed to normoxia or hypoxia. After 16 h, apoptosis was 
determined in hypoxic cells and set to 100%. B, HL-1 cardiomyocytes 
transfected with either negative siRNA or with  specific P2Y4 siRNA were 
exposed to normoxia or hypoxia. After 16 h apoptosis was determined in 
hypoxic cells as described.C, HL-1 cardiomyocytes transfected with either 
negative siRNA or with specific P2Y6 siRNA were exposed to normoxia or 
hypoxia. After 16 h apoptosis was determined in hypoxic cells as described. 
Values are the means ± S.E.M. from 3 individual experiments run in triplicate 
*p<0.05 vs. control siRNA-negative treated cells, Student “t” test. H= 
apoptosis value under hypoxic conditions after subtraction of the apoptosis 
value detected under normoxic conditions.  
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4.10 Both G proteins and protein kinase C are involved in the 
cardiomyocyte apoptosis induced by hypoxia and ATP 
 
To shed some light on the post-receptor mechanisms involved in 
hypoxia and ATP-induced apoptosis of HL-1 cardiomyocytes, we 
also performed experiments with either the selective Gi protein 
inhibitor PTX, the pan-G protein inhibitor GDP-β-S, or the protein 
kinase C inhibitor GF. Both G-protein inhibitors partially but 
significantly inhibited hypoxia-associated apoptosis, while the 
protein kinase C inhibitor showed a non statistically significant 
trend to a reduction (Figure 4.13). When apoptosis was induced by 
exposure to high ATP concentrations, a highly significant 
reduction of cell death was observed in the presence of either PTX 
or GF. No significant effects were induced by these agents on 
normoxic cells.  
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Figure 4.13: Effect of various inhibitors of signalling cascades on cardiomyocyte 
apoptosis induced by ischemic hypoxia or by ATP. A, The protein kinase C 
inhibitor GF (1-2 µmol/L), the Gi protein inhibitor PTX (50-100 nmol/L) and the 
non specific G-protein inhitor GDP-β-S  (250-500 µmol/L) were added to cells 1 h 
before hypoxia. Parallel samples receiving these same inhibitors were maintained 
under normoxic conditions. At the end of the incubation, the extent of apoptosis in 
hypoxic cells was determined by assessing enrichment of  mono/oligonucleosome 
in cells via ELISA assay, and set to 100%. H= apoptosis value under hypoxic 
conditions after subtraction of the apoptosis value detected under normoxic 
conditions.B, HL-1 cells were treated with ATP at the indicated concentrations. 
PTX (100 nmol/L) and GF (1µmol/L) were added to cells 1 h before ATP addition 
(250 µmol/L). At the end of a 24 h incubation, apoptosis was determined by 
assessing enrichment of mono/oligonucleosome in ATP treated cells via ELISA 
assay in the absence or presence of the indicated inhibitors and set to 100%. 
Values are the mean ± S.E.M. from 3 individual experiments, run in triplicate $: 
p<0.01 versus corresponding  ATP control values, Student “t” test.  
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5 
DISCUSSION 
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Extracellular nucleotides play important regulatory roles within 
the cardiovascular system. ATP and UTP are released from either 
the heart or from other sources during cardiac ischaemia and 
patients with myocardial infarction have higher plasma levels of 
both nucleotides (Vassort, 2001; Wihlborg et al., 2006).  
Here, we show that ATP and P2 receptors play a key role in 
hypoxia-induced apoptosis of HL-1 cardiomyocytes, that have 
been shown to express various P2X and P2Y receptor subtypes 
(Mazzola et al., 2008). 
Specifically, we demonstrate that (i) ischemic/hypoxic stress is 
associated to rapid ATP release from cultured cardiomyocytes, 
and, (ii) that distinct P2 receptor subtypes regulate cardiomyocyte 
death, with both pro- and anti-apoptotic effects. These effect are 
likely mediated by direct stimulation of P2 receptors by ATP, 
although we cannot exclude that other concomitantly released 
nucleotides (e.g., uracil nucleotides, see also below) are also 
involved. Moreover, by using both pharmacological inhibitors and 
gene silencing of selected P2 receptor subtypes via small RNA 
interference, we provide compelling evidence for a specific role of 
the ligand-gated P2X7 receptor and the G-protein-coupled P2Y2 
receptors in hypoxia-induced cardiomyocyte apoptosis. Our data 
also suggest a protective role for the P2Y4 receptor; conversely, no 
effects are apparently induced by the co-expressed P2Y6 receptor. 
Finally, we provide some initial hints involving G-proteins and 
protein kinase C in the post-receptor mechanisms at the basis of 
hypoxia- and ATP-induced cardiomyocyte apoptosis. 
These data are particularly relevant to the pathogenic 
mechanisms at the basis of myocardial damage during 
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hypoxic/ischemia event in patients. Under physiological 
conditions, in both rat and human heart, as well as in human 
plasma, extracellular ATP levels have been estimated to be 
approximately around 20-40 nmol/L (Forrester, 1972; Kuzmin et 
al., 1998). However, upon hypoxia/ischemia, due to both increased 
exocytosis from cell’s vesicular pool and to release from the 
cytoplasm (see also below), these levels are markedly increased to 
reach micromolar concentrations (Dutta et al., 2004). More 
recently, during myocardial infarction, human venous plasma 
levels of UTP have been also demonstrated to increase to about 
10% of the ATP concentrations (Wihlborg et al., 2006). It has 
been postulated that, under these conditions, increases of 
nucleotides release is originally meant at augmenting heart 
function via a positive inotropic effect mainly exerted through the 
myocardial P2Y2 receptor (although also P2Y4 and P2Y6 receptors 
may contribute) (ibidem). However, if heart reperfusion is 
impaired or totally prevented and nucleotides are not removed 
from the myocardium, their local concentrations (especially those 
of ATP) may increase to toxic levels and contribute to myocardial 
cell death. This hypothesis is consistent with our present data 
demonstrating that ATP is indeed released from cardiomyocytes 
very early after an hypoxic/ischemic insult, and that this release is 
associated to apoptosis induction. In our model, the early release 
of ATP does not involve cell lysis, since it is not associated to 
LDH release. Moreover, in line with previous data, ATP release 
occurs via the maxi-anion channel, which is highly expressed in 
the heart and rapidly activated by hypoxic stress (Sabirov and 
Okada, 2005). A causal relationship between ATP release and the 
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subsequent cardiomyocyte death is confirmed by the 
demonstration that both non selective P2 receptor blockers, the 
maxi-anion channel blocker GdCl3 and apyrase (which degrades 
nucleotide triphosphates into nucleotide monophosphates) were 
able to inhibit cardiomyocyte apoptosis (Sugimoto et al., 2009). In 
line with these findings, apyrase expression was increased in 
pathological samples of patients with ischemic heart disease 
(Erlinge and Burnstock, 2008; Kittel et al., 2005). 
As highlighted above, our data point to differential roles of 
various P2 receptors in cardiomyocyte viability during hypoxic 
ischemia. In detail, the pro-apoptotic role of the P2Y2 receptor 
under hypoxic conditions is in line with previous data 
demonstrating that this is indeed the most expressed P2 receptor in 
the heart which undergoes upregulation in the human failing heart 
(Hou et al., 1999). Moreover, 3 single nucleotide polymorphisms 
(SNPs) of the human P2Y2 receptor gene have been associated 
with MI and proposed as genetic markers for MI in Japanese men 
(Wang et al., 2009). The P2Y2 receptor also promotes a profibrotic 
response in isolated rat myocardial fibroblasts; moreover, in mice 
lacking this receptor subtype, extracellular nucleotides are no 
longer able to increase the expression of the two pro-fibrotic 
markers plasminogen activator inhibitor type 1 and alpha-smooth 
muscle actin (Braun et al.). Regarding the P2X7 receptor, despite 
abundant information on the role of this receptor in induction of 
apoptosis in macrophages, monocytes, microglia and other cell 
types (Baraldi et al., 2004), very little is known on its presence and 
role in MI. While no direct evidence for the presence of P2X7 in 
rodent heart is available, in dog, this receptor subtype has been 
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indeed originally cloned from heart cDNA (Roman et al., 2009). 
Significant levels of P2X7 have been found in human myocardial 
samples from both normal subjects and patients with chronic heart 
failure (Banfi et al., 2005). Moreover, a loss-of-function P2X7 
polymorphism has been reported in patients with heart failure 
(Eslick et al., 2009), but the relevance of this finding is unknown. 
More recently, an indirect involvement of P2X7 in the regulation 
of cardiomyocyte viability has been suggested by the 
demonstration that pannexin-1/P2X7 channels mediate the release 
of cardioprotectants induced by ischemic pre- and post-
conditioning (Vessey et al., 2010). Therefore, this is the first time 
that, based on both pharmacological and gene-silencing data, P2X7 
is unequivocally implicated in induction of ischemia-associated 
cardiomyocyte death.  
Our data also highlight a protective role for P2Y4. Previous data 
have shown that, in cultured hypoxic cardiomyocytes, activation 
of some P2Y receptors by UTP reduced LDH release (Yitzhaki et 
al., 2005), prevented intracellular calcium elevation, maintained an 
increased level of intracellular ATP (Yitzhaki et al., 2006) and 
preserved mitochondrial activity (Yitzhaki et al., 2007). In line 
with these findings, in vivo experiments showed that UTP 
administration reduced infarct size and improved myocardial 
function (Shainberg et al., 2009). However, the exact P2 receptor 
involved was not univocally identified in these studies. UTP can 
activate both P2Y2 and P2Y4 receptors (Abbracchio et al., 2006); 
the present data indeed suggest, for the first time, that it is the 
latter that mediates UTP-induced protection. Regarding the P2Y6 
receptor subtype, that has been proposed to mediate positive 
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inotropic effects (Wihlborg et al., 2006), recent papers have 
indeed involved this receptor in pressure overload-induced cardiac 
fibrosis (Erlinge and Burnstock, 2008; Nishida et al., 2008). 
However, our data suggest that, despite playing a role in heart 
remodeling during chronic heart failure, this receptor is not 
directly involved in regulation of cardiomyocyte viability during 
acute hypoxic stress.  
Finally, the present data shed some light on the post-receptor 
mechanisms involved in P2 receptor regulation of cardiomyocyte 
viability. In our model, inhibition of both G-proteins and PKC 
resulted in apoptosis reduction (although, for the PKC inhibitor, 
this effect did not reach statistical significance). These data are in 
line with our proposal that the G-protein coupled P2Y2 receptor 
participates to cardiomyocyte death under hypoxic conditions. 
Regarding the involvement of PKC in cell death, both protective 
and pro-apoptotic effects have been reported. Whereas activation 
of PKCδ during reperfusion mediated damage, activation of PKCε 
before ischaemia protected the heart (Churchill and Mochly-
Rosen, 2007). In particular, regulation of PKCδ is critical for cell 
survival and caspase-mediated cleavage of PKCδ in the nucleus 
signals an irreversible committment to apoptosis (Reyland, 2007). 
Regarding the link between P2Y receptors and PKC, P2Y2 is 
indeed known to couple to the Gq protein that, by activating 
phospholipase C, promotes the formation of inositol phosphates 
and diacyl-glycerol, that, can, in turn, activate PKC (Abbracchio et 
al., 2006). Thus, PCK could be directly recruited by the P2Y2 
receptor during ischemic/hypoxic stress and participate to 
induction of cell death. However, in other cell systems, PKC has 
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also been reported to mediate P2Y2 receptor desensitization and 
sequestration (Garrad et al., 1998), which should inhibit cell death. 
Alternatively, PKC could be recruited by the P2X7 receptor, which 
also induces cardiomyocyte apoptosis in our model. A direct link 
between P2X7 and PKC is indeed supported by evidences obtained 
in other experimental models. In osteoclasts, activation of P2X7 
causes isoform-specific translocation of protein kinase C 
(Armstrong et al., 2009); moreover, in granule neurons, P2X7 
receptor is mainly activated in PKC-dependent manner (Ortega et 
al.). Globally, we demostrated that both P2Y2 and P2X7 contribute 
to cardiomyocyte apoptosis induction during ischemic/hypoxia. 
We belive that a pharmacological modulation of this receptor 
subtypes may have important therapeutic implications and our 
study set the basis for the development of novel cardioprotective 
agents that target specific P2 receptor subtypes. 
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 Abbreviations 
 
ACE                                angiotensin-converting enzyme  
AMI                                 acute myocardial infarction  
CRP                                 C-reactive protein  
CVD                              cardiovascular diseases  
cysLTs                           cysteinyl-leukotrienes  
DMEM                         Dulbecco's Modified Eagle Medium  
ER                                 endoplasmic reticulum  
GPCR                            G protein-coupled receptor 
IL                                   interleukin 
IUPHAR                        International Union of Pharmacology 
LDH                             lactate dehydrogenase  
MI                                    myocardial infarction  
MPTP                           mitochondrial permeability trasition pore  
NA                               noradrenaline  
NO                               nitric oxide  
NTPD                              ectonucleotidase  
SNPs                            single nucleotide polymorphisms  
tPA                               tissue-type plasminogen activator  
VSMC                             vascular smooth muscle cells 
VCAM-1                         vascular cell adhesion molecule-1  
2MeSADP                     2-methylthioadenosine 5'-diphosphate  
PAI-1                            plasminogen activator inhibitor  
RB2                               Reactive blue 2 
